Asosiy kontentga oʻtish
Sharh maqola

Dendritic cell–derived exosomes for cancer therapy

Jonathan M. PittINSERM Unit U1015, Villejuif, FranceFabrice AndréInstitut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, FranceSebastián AmigorenaINSERM Unit U932, Institut Curie, Paris, FranceJean‐Charles SoriaDITEP - Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] (Gustave Roussy. 114, rue Édouard-Vaillant. 94805 Villejuif Cedex - France - France)Alexander EggermontInstitut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, FranceGuido KroemerKarolinska University Hospital [Stockholm] (Huddinge 141 86 Stockholm - Sweden)Laurence ZitvogelUniversité Paris Sud, Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France
2016en
ABI

Annotatsiya

DC-derived exosomes (Dex) are nanometer-sized membrane vesicles that are secreted by the sentinel antigen-presenting cells of the immune system: DCs. Like DCs, the molecular composition of Dex includes surface expression of functional MHC-peptide complexes, costimulatory molecules, and other components that interact with immune cells. Dex have the potential to facilitate immune cell-dependent tumor rejection and have distinct advantages over cell-based immunotherapies involving DCs. Accordingly, Dex-based phase I and II clinical trials have been conducted in advanced malignancies, showing the feasibility and safety of the approach, as well as the propensity of these nanovesicles to mediate T and NK cell-based immune responses in patients. This Review will evaluate the interactions of Dex with immune cells, their clinical progress, and the future of Dex immunotherapy for cancer.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

4 ta iqtibos0 ta foydalanilgan manba